Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer's Inspra has been a commercial flop, but now a post-marketing study has shown positive results in a broader patient population

You may also be interested in...



American Heart Association Research, In Brief

Outcomes Study Resuscitates Natrecor

American Heart Association Research, In Brief

Outcomes Study Resuscitates Natrecor

Pfizer Backs Out Of Cardiovascular R&D

Drug giant exits obesity, anemia, disease-modifying osteoarthritis and more.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel